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Summary A panel of 21 small cell lung cancer cell (SCLC) lines were examined for the presence of
Transforming growth factor P receptors (TGF3-r) and the expression of TGFP mRNAs. By the radioreceptor
assay we found high affinity receptors to be expressed in six cell lines. scatchard analysis of the binding data
demonstrated that the cells bound between 4.5 and 27.5 fmol mg' protein with a KD ranging from 16 to
40 pM. TGFP, binding to the receptors was confirmed by cross-linking TGFP, to the TGFP-r. Three classes of
TGFI-r were demonstrated, type I and type II receptors with M, = 65,000 and 90,000 and the betaglycan (type
III) with Mr= 280,000. Northern blotting showed expression of TGFP, mRNA in ten, TGFP2 mRNA in two
and TGFP3 mRNA in seven cell lines. Our results provide, for the first time, evidence that a large proportion
of a broad panel of SCLC cell lines express TGFP-receptors and also produce TGFI mRNAs.
The TGFP family consists of several members of structurally
related proteins. The first member of this family to be cloned
was TGFPi1 (Derynck et al., 1985). To date three other
members have been cloned and described TGFP2 (Miller et
al., 1989b; Madisen et al., 1988; de Martin et al., 1987) from
murine and human source. TGFP3 (Miller et al., 1989a) from
murine source and TGFPI4 from chicken embryonic tissue
(Jakowlew et al., 1988). These members form a complex
network of interacting ligands. The role for each of these has
not been clearly elucidated but the expression pattern in the
mouse embryo suggest a role in differentiated role in embryo-
genesis (Pelton et al., 1991). The TGFI3 family of peptides
exerts both stimulatory and inhibitory effects depending on
cell type examined (Barnard et al., 1990).
Receptors for TGFP have been demonstrated in a variety
of normal cells of both epithelial and mesenchymal origin as
well as in several malignancies (Frolik et al., 1984; Tucker et
al., 1984; Massague & Like, 1985; Wakefield, 1987). At
present five distinct TGFI3-r have been identified, type I
(Mr = 60-70,000), type II (85-110,000), type III
(200-400,000), type IV (60,000) and type V (40,000). The
type II and III receptors have recently been cloned (Lin et
al., 1992, Wang et al., 1992). In addition a TGFP binding
protein (150,000 and 180,000) has been described, which binds
TGFPi3 but not TGFP2 (MacKay & Danielpour, 1991). The
type I and II receptors are the most probable candidates as
the mediator of the signal induced by TGFP (Boyd & Mas-
sague, 1989; Laiho et al., 1990). The type III receptor is
believed to be a surface associated proteoglycan, which binds
TGFP and ultimately releases it (Andres et al., 1989) or is
internalised with TGFP (Massague, 1990). The type IV recep-
tor has been identified in pituitary cells, but its function has
not been established (Cheifetz et al., 1988). The function of
the type V receptor, which has been purified from bovine
liver, is unclear at present (O'Grady et al., 1991). Several
malignancies have been screened for the presence ofTGFP-r,
but in human lung cancer the data is very sparse. A few
studies have demonstrated that TGFI3 mRNA was expressed
in only non-SCLC (NSCLC) cell lines (Soderdahl et al.,
1988; Derynck et al., 1987; Bergh, 1988). In another study all
of ten SCLC cell lines examined were found to be TGF,B
mRNA negative (Lagadec et al., 1991). In these studies the
TGFP isoform investigated was not specified, but most prob-
ably it was TGFPI3 mRNA.
These data are the basis for the concept that only NSCLC
cell lines can produce TGFP (for review, see Pelton & Moses,
1990).
In the present study we have examined the presence of
TGFf-r and the production of TGFP mRNA in a panel of
21 SCLC cell lines established in five different laboratories.
The results showed that a relatively high proportion of SCLC
cell lines carried high affinity TGFI-r and expressed TGF3
mRNA. Coexpression ofTGFI-r and TGFP was found in six
SCLC cell lines.
Materials and methods
Cell lines
SCLC cell lines were cultured in 150 cm2 flasks at 37°C under
standard conditions in medium containing 10% foetal calf
serum (Flow Laboratories, Irvine, Scotland) without anti-
biotics. We have previously reported in detail the growth
morphology and tissue culture media for these cell lines
(Damstrup et al., 1992). Twenty-one SCLC cell lines estab-
lished from 17 patients in five different laboratories were
examined. Eight cell lines were established at Dartmouth
Medical School, Hanover, NH, USA (DMS), seven cell lines
were established at Gronningen Lung Cancer Center, Gron-
ingen, the Netherlands (GLC), two cell lines were established
at the National Cancer Institute, Bethesda, MD, USA (NCI),
two cell lines were established in Marburg, Germany (24H
and 86M1), and two cell lines were established in our own
laboratory Copenhagen, Denmark (CPH). The origin and
establishment of the cell lines has been described elsewhere
(Pettengill et al., 1980; Carney et al., 1985; de Leij et al.,
1985; Bepler et al., 1987; Berendsen et al., 1988; Engelholm et
al., 1986). AKR-2B, a mouse fibroblast cell line, which
previously has been reported TGFJ-r positive (Tucker et al.,
1984) was cultured in Eagle's minimal essential medium (Flow
laboratory) supplemented with 10% foetal calf serum, and
used as a positive control for TGFP binding. This cell line
was kindly provided by Professor H.L. Moses, Vanderbilt,
University, Tennessee. All cell lines were routinely checked
for, and found free of, mycoplasma infection.
Cells growing as monolayer cultures were assayed in
35 mm 6-well tissue dishes for radioreceptor assays. Cells
were subcultured and used within 24 h of plating. Cells grow-
ing as floating aggregates were subcultured and assayed in
microfuge tubes within 24 h of subculturing.
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Growthfactors
Porcine TGFPi1 was purchased from British Biotechnology
Ltd, Oxford, England and/or was a gift from Bristol-Meyers-
Squibb, Pharamaceutical Research Institute, Seattle, USA.
Human recombinant EGF and TGFa was purchased from
Bissendorf Biochemicals, Hannover, Germany.
'25I-labelled TGF,I with a specific activity of
100-180pCipg` (2.5-4.5Cimol%), was purchased from
New England Nuclear, Boston, USA. The binding activity of
125I-labelled TGFPI was checked at regular intervals using the
positive control cell line AKR-2B. The '25I-labelled TGFP1
was used within 4 weeks of fresh lot date.
Radioreceptor assay
The procedure has been described previously (Massague &
Like, 1985; Massague, 1987). Cells growing as monolayer
culture were plated in 35 mm 6-well dishes, usually at
2-5 x 105cells per well, the day before experiments were
performed. The cells were washed for 60 min with binding
buffer (128 mM NaCl, 5 mM KCI, 5 mM MgSo4, 1.2 mM
CaCl2, 50 mM HEPES, pH 7.5 and 2%-BSA). After washing,
the cells were incubated with 5-1O pM 125I-labelled TGF,1
and increasing levels of native unlabelled TGFPI ranging
from 0 to 200 pM, the volume of incubation being adjusted
to 1 ml. After 2 h incubation at 20°C the reaction was stop-
ped by washing the plates three times with ice cold binding
buffer without albumin. After the final wash, the cells were
solubilised in solubilisation buffer (128 mM NaCl, 0.25 mM
EDTA, 0.5 mM Tris, pH 7.5 and 1% v/v Triton X-100). An
aliquot of the supernatant was counted in a Beckmann II
gamma counter (70% efficiency). Protein concentration was
detennined with the BCA protein kit (Pierce Europe, B.V.,
Oud Beujerland, The Netherlands) (Smith et al., 1985). Cells
growing as floating aggregates or cells easily detectable were
assayed, as single cell suspensions, in 1.5 ml sigmacote
(Pierce) treated microcentrifuge tubes. Viability after obtain-
ing a single cell suspension, assessed by trypan blue exclusion
test, was 90-95%. After incubation the reaction was stopped
by centrifuging at 5,500 g for 3 min and the cell pellet was
resuspended three times in ice cold binding buffer without
albumin. After the final wash, the cell pellet was solubilised
as above. Maximal binding (Bm.) was calculated as fem-
tomol mg-' protein by Scatchard analysis of the binding data
(Scatchard, 1949). Specificity of the binding was determined
in specificity experiments with TGFPI, EGF and TGFa as the
displacing agents. The displacing agents were added at the
same time as the '25I-labelled TGFPI.
Cross-linking
Washed single cell (2-5 x 106) suspensions were incubated
with 40 pM '25I-labelled TGFPI in the presence or absence of
a 100-fold excess of unlabelled TGFP1. The incubation pro-
ceeded for 4 h at 4°C. After the final wash, the cell pellet was
resuspended in 950 p1 binding buffer without BSA before
50 p1 of 5 mM cross-linking agent disucinimidyl (DSS)
(Pierce, France), freshly dissolved in DMSO, was added. The
cross-linking reaction proceeded for 15 min at 4°C and was
stopped by centrifuging and washing the pellet in a Tris-
containing buffer. Finally the cell pellet was resuspending in
80 p1 solubilisation buffer, 10 p1l cocktail 1 and 10 p1l cocktail
2 as described earlier (Massague, 1987). The resulting super-
natant was boiled for 5 min in sample buffer with 50 mM
dithiothreitol (Pierce). One hundred fig protein/lane was run
on a 5, 7 or 10%, 8 x 16 cm SDS-PAGE gel. After staining
with Coomassie brilliant blue and destaining, the dried gel
was exposed to an X-ray film (Amersham) with an intensify-
ing screen at - 80°C.
Northern blotting
RNA was extracted by the single-step acid guanidinium
thiocyanate-phenol-chloroform method (Chomczynski & Sac-
chi, 1987). Ten pg total RNA samples were electrophoresed
through denaturing agarose gels containing 2.2 M for-
maldehyde, and transferred to nylon membranes (GeneScreen
Plus, NEN DuPont) as recommended by the supplier. Radio-
labelled probes were prepared by the random priming
method (Feinberg & Vogelstein, 1983) using [a-32P]dCTP and
a commerical kit (both from Amersham). The blots were
sequentially hybridised with human probes for TGFII and for
P-actin. The probes for TGFI31 were a 2.0 kb full length
cDNA (Kasid et al., 1988) obtained from the American Type
Culture Collection (No. 59954) and a 267 bp fragment span-
ning nucleotides 1773-2040. The probe for TGFP2 mRNA
was a 442 bp murine fragment of the plasmid pmTGFb2-9a
(Miller et al., 1989b). The TGFI33 probe was a 609 bp murine
fragment of the plasmid pmTGFP3-IIb (Miller et al., 1989a).
The TGFP2 and TGFP3 probes were obtained from Professor
H.L. Moses, Vanderbilt University. RNA extracted from
murine heart and lung was used as positive controls. The
P-actin probe was a 2.1 kb BamHI fragment of the plasmid
pHFj3A-1 (Gunning et al., 1983). The membranes were pre-
hybridised, hybridised and washed as recommended by the
supplier, and exposed to an X-ray film at - 80C with an
intensifying screen.
Results
Receptor binding studies
Saturation of the receptors were reached with a TGFPI3 con-
centration in the range of 50 to 100 pM (exemplified in
Figure 1). Non-specific binding, defined as the cell associated
radioactivity in the presence of a large excess of unlabelled
TGFPI, was relatively high but was an inverse function of
binding capacity - 23% in AKR-2B with a Bm., of 70
femtomolmg-' protein and 70% in GLC 19, assayed as a
single cell suspension, with a Bm., of 4.5 femtomolmg-'
protein. This relationship has also been described in other
cell types (Massague, 1987). As about half the cell lines grew
as floating aggregates and half as monolayer cultures, we
chose to relate all binding data to protein concentration.
Scatchard analysis of the binding data showed that cells
bound between 5 and 27 fmolmg-' protein with a KD of
16-40pM (Table I).
The specificity of the TGFI-r/ligand binding was deter-
mined using different displacing agents. The specificity of
1251I-labelled TGF,I binding to GLC 3 is shown in Figure 2.
It was found that EGF and TGFa, which both binds to the
EGF-receptor (Carpenter et al., 1983) did not displace 125i-
labelled TGFPI. For all cells tested and found positive in the
radioreceptor assay, binding was in all cases specific and
saturable.
Cross-linking studies
TGFP, binding to the receptors was further visualised by
cross-linking the ligand-receptor complex with DSS. Figure 3
illustrates the affinity labelling results of eight SCLC-cell
lines. Following electrophoresis on a SDS-PAGE gel, specific
TGFiI binding was seen as bands with calculated Mr of
65,000, 90,000 and 280,000; these bands correspond to the
type I, II and III TGFI-r. The presence of excess unlabelled
TGFPI resulted in the disappearance of these bands, demon-
strating that the binding was specific. Seven SCLC-cell lines
were TGF3-r positive in the affinity labelling experiments
(Table I).
Northern blotting studies
The cell lines were examined for the production of TGFI3
mRNA. Figure 4a illustrates a Nothern blot analysis of 20
cell lines using the full length TGFPi cDNA probe. The
TGFP, mRNa is seen as a band of approximately 2.5 kb.
Results using the 267 bp TGFiI fragment was similar (data
not shown). Nineteen cell lines were hybridised with probesTGFPi RECEPTORS AND TGFP IN SCLC 1017
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Figure 1 TGFP binding to a SCLC cell line. CPH 54A was
incubated with 5 pM '25l-labelled TGFI and increasing concen-
trations of unlabelled TGFP, as described in Materials and
methods. Insert: Scatchard plot of the receptor specific binding
per 100 ig protein (B) and the free ligand concentration (F). KD
is given by the slope of the curve. Bmax is given by the x-axis
intercept. * Total binding; 0 Receptor specific binding; A Non
specific binding.
for TGFPi2 and TGFPI3. In two cell lines (Figure 4b) TGFP2
mRNA was detected as a faint band of 3.9 kb. TGFPi2
mRNa, size approximately 3.5 kb, was found in seven cell
lines (Figure 4c). Blots were rehybridised with the 1B-actin
probe to demonstrate equal loading in all lanes. The intensity
of staining with the TGFP probe therefore semiquantifies the
TGFJ3 mRNA content.
The results for all binding data, affinity labelling and
Northern blot analysis are summarised in Table I. Six of the
TGF3-r positive cell lines also expressed TGFP (Table I).
Table I Summary of the TGFP receptor
lines
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Figure 2 Specificity of TGFPI binding. GLC 3 was incubated
with 5 pM 125I-labelled TGFJI and displaced with increasing
levels of: * EGF; 0 TGFa; V TGFP,: Binding is expressed in
% of maximal specific binding, 100% being 7.300 CPM mg-'
protein.
Discussion
This is to our knowledge the first study in which a broad
panel of SCLC cell lines has been studied for the presence of
TGFP-receptors and the expression of TGFfi mRNA. The
panel of SCLC cell lines, established in five different
laboratories and cultured in different media, is probably a
representative cross-section of SCLC cell lines. In order to
standardise our radioreceptor assay, we carried out the nor-
mal time- and temperature course experiments as described
and TGFP expression in SCLC cell
Bound TGFJ Receptor TGfJ mRNA
Cell line fmolmg-' KD (pM) I II III 1 2 3
DMS 53 - - - - - + (+ -
DMS 79 - - - - - + - -
DMS 92 - -
DMS 114 26.6 2.la 40.3 ±4.5 - - + + (+) +
DMS 153 - - - - - + _ _
DMS 273 5.2±0.5 20.6 2.3 - (+) + + - (+)
DMS 406 - -
DMS 456 - -
GLC 2 - - _ _ _ _ _ +
GLC 3 10.7 1.1 22.7 1.4 - - + + - +
GLC 14 - -
GLC 16 - - + + - - - _
GLC 19 4.5±1.1 16.1±4.4 + + - + - -
GLC 26 - - - -
GLC 28 - - - -
24H - - - - _ _ _ +
86M1 - - - - - NT NT NT
NCI H69 - - - - -
NCI N417 - - - - - + NT NT
CPH 54A 27.6 2.6 25.2 6.2 + + + + - (+)
CPH 54B 21.3 3.9 23.0 6.2 + + + + - +
Bmax and KD were determined as described in the text. TGFP-r was detected by
cross-linking studies. TGFP,, TGFP2 and TGFP3 mRNA was detected by Northern
blotting. -: Negative. +: TGFJ3 receptor or mRNA detected. (+): Faint band. a:
Mean of 3-4 values ± s.d. NT: not tested.C-,
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Figure 3 Affinity labelling of the TGF,B receptor. Cells were incubated with '25l-labelled TGFP, as described in Materials and
methods, the receptor complex was cross-linked with DSS and size fractionated on either a, 5% SDS-PAGE gel to demonstrate the
high molecular weight betaglycan (type III receptor) or b, 10% gel to demonstrate the receptor type I and II. c, 7% gel for 3 GLC
cell lines. For each cell line two lanes were run: - 40 pM '251-labelled TGFP,; + 100-fold excess of unlabelled TGFl3. Molecular
weight standards from Bio-Rad were co-electroforesed. Roman numerals indicates the type I and II TGFP-r. Arrow indicate the
TGFP type III receptor.
elsewhere (Frolik et al., 1984; Tucker et al., 1984), and found
that the binding was stable for a prolonged period of time at
20°C. Furthermore we found that the receptors could not be
demonstrated if the protein concentration was lower than
150 jLl ml-'. We have previously demonstrated, in the same
cell lines, studying the EGF-receptor that this critical protein
level was also required to detect the EGF-receptor (Dam-
strup et al., 1992). Studies on other receptor systems such as
the estrogen receptor has also demonstrated this critical pro-
tein limit (Skovgaard Poulsen, 1981). Therefore, to avoid
underestimating binding capacity or falsely classify a SCLC
cell line as TGFP-r negative, we only drew conclusions on the
TGF3-receptor state in a cell line if the protein concentration
was in the range of 200-600pgml-'.
Analysis of the binding data demonstrated that Scatchard
plots in some cell lines were curved near saturation of the
receptors. However, it was not possible, with the ligand
program developed by Munson and Rodbard (Munson &
Rodbard, 1980), to resolve the Scatchard plots into two or
more compartments. Other investigators have, in normal rat
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Figure 4 Northern blot analysis of TGFI expression in SCLC. a, Probed with the TGFI, cDNA, b, with TGFP2 and c, with
TGFP3. The resulting 7 day autoradiography is shown. The 2.5 kb TGFP,mRNA, the 3.9 kb TGFP2 mRNA and the 3.5 kb TGFP3
mRNAs are indicated. Transcript size for TGFJI was determined with reference to the 18 and 28S bands. Transcript sizes for
TGFP2 and TGFP3 were determined with reference to mRNA molecular weight markers with band sizes 1.4, 2.4, 4.4, 7.5 and 9.5 kb
(Life Technologies). The P-actin probing indicate that the lanes were loaded equally. The band seen in all cell lines probed with
TGFPI represents non-specific binding the 28S (4.8 kb) ribosomal band. *Murine lung mRNA is included as a positive control for
the TGFPi2 and TGFP3 probes.
kidney cell (NRK), also only demonstrated one class of
TGFP receptors, despite the fact that cross-linking studies
with NRK cells have demonstrated that these cells express
type I, II and III receptors (Wakefield, 1987; Massague &
Like, 1985; Segarini et al., 1987). Resolving the data with a
single class receptor from the linear part of the Scatchard
plot demonstrated high affinity receptors in six SCLC cell
lines (Figure 1, Table I). The dissociation constant was in all
cases characteristic for TGFP binding (Massague, 1987;
Wakefield, 1987). Maximal binding varied from 4.5 to
27.5 fmol mg-' protein. Binding of 251I-labelled TGFI,, to the
positive cells was specific as only TGFP could displace the
labelled TGFBI. EGF and TGFa did not influence TGFP
binding (Figure 2).
The results obtained from the radioreceptor assay and the
displacement studies demonstrated that a large proportion of
the SCLC cell lines examined carried specific high affinity
TGFI-r. Our results are in part corroborated as one of these
cell lines, GLC 19, has previously been reported to be growth
inhibited by TGFP (Lagadec et al., 1991). However, in the
cited study the cells were not examined for the presence of
TGFI-r.
To verify that the binding of TGFPI was in fact to the
TGF3-r, the cell lines were tested by cross-linking. After size
fractionation on SDS-PAGE gels, all cell lines found to be
TGF3-r positive in the radioreceptor assay also displayed one
or more specific bands with calculated Mr = 65,000, 90,000
and 280,000 (Figure 3). These sizes include reduced TGFP
with a Mr ofapproximately 12,000. The Mr of the correspond-
ing receptors is therefore 53,000, 78,000 and 270,000. The
TGFPI receptors have previously been reported as having
these calcualted molecular weight (Massague, 1987; Mas-
sague, 1990). This provides further evidence that TGFP1
binding was to the TGFI-r. One cell line, GLC 16, expressed
the type I and II TGF,B-r in this assay. We could, however
not demonstrate the receptor in the radioreceptor assay, even
using a very high protein concentration (>800 fig ml-'). The
binding capacity in this cell line could be so low that it was
below the detection limit in the radioreceptor assay. In the
same cell line, we have found that the receptor was func-
tional in that exogenously added TGFP, acted as a growth
inhibitor (N0rgard, P., unpubished observation).
We also examined the expression of TGF,B mRNAs in the
panel. In 10/20 SCLC cell lines TGFI,B mRNA could be
detected (Table I, Figure 4a). In GLC 3 and faintly in DMS
153 an additional band of 1.7 kb was found, the nature of
this band is unclear. A mRNA with this approximate size has
also been found in male mice germ cells (Watrin et al., 1991).
We examined 19 of the SCLC cell lines with a probe for
TGFP2 mRNA (Figure 4b), and in two cell lines (DMS 53
and DMS 114) a single transcript of 3.9 kb was demon-
strated. This is in accordance with one of the TGFP2 trans-
cripts reported in other human cell lines (Mori et al., 1990),
whereas none of the additional TGFI2, mRNAs reported
(Jakowlew et al., 1991; Mori et al., 1990; Miller et al., 1989b)
were detected in the investigated cell lines.
We have previously examined 15 of the cell lines in our
panel for expression of phosphorylated retinoblastoma gene
product (pRb) (Rygaard et al., 1990). Only the two cell lines
(DMS 53 and DMS 114) in which TGFP2 mRNA was
qt co
J (0
0D0
0) (O (0
uJ uJ
u
0i
a)
co I
I Z
z
z
28 S-
TGFI3i-
18S-
p-actin
7.5 kb-
4.4 kb -
TGFj2-
2.4 kb-
4.4 kb -
TGFI3 -
2.4 kb-
1.4 kb -
1-actin
a
b
c1020 L. DAMSTRUP et al.
detected, were found to express pRb, and immuno-
cytochemistry demonstrated nuclear localisation of pRb
(Rygaard, K., unpublished observation). Other studies
(Templeton et al., 1991) have suggested that pRb is func-
tional only when phosporylated and located in the nucleus. It
has recently been reported that the pRb activates the expres-
sion of TGFI32 (Kim et al., 1992). Provided that the charac-
teristics of pRb in DMS 53 and DMS 114 indicates that the
protein is functional, our finding that TGFP2 was detected
exclusively in the two cell lines also expressing a 'functional'
pRb, agrees with the concept that expression of TGFP2 is
activated by pRb.
Seven cell lines expressed the 3.5 kb TGFP3 mRNA (Figure
4c), corresponding to the reported size in other human malig-
nant tissue (Dijke et al., 1988). Two of these cell lines (GLC
2 and 24H) also expressed a transcript with a size of approxi-
mately 2.5 kb, which is the transcript size of TGFPI mRNA,
however, these two cell lines did not express TGFPi mRNA.
The probing for TGFP2 and TGFP3 was performed with a
murine probe, and there may not be perfect homology to the
human mRNA. This implies that additional cell lines could
be positive following probing with a human probe. Taken
together a total of 12 of the 20 examined SCLC cell lines
expressed TGFP mRNA. This finding is in contrast to earlier
studies, where a few cell lines have been examined and found
to be TGFP mRNA negative (Soderdahl et al., 1988;
Derynck et al., 1987; Lagadec et al., 1991). In one of these
studies (Lagadec et al., 1991) the examined cell lines included
GLC 14, 16 and 19, NCI H69 and N417, all these were
TGFP mRNA negative. These cell lines were also included in
our panel, but we found expression of TGFPI mRNA in
GLC 19 and NCI N417. This transcript was detected as a
2.5 kb band using both the full length cDNA and the 267 bp
TGFPI fragment. The difference betwen our results and the
previous reported study (Lagadec et al., 1991), is not appar-
ent, but could be due to a difference in sensitivity.
Our results based on a panel of 21 SCLC cell lines have
demonstrated that TGFI3 receptors were present in seven of
21 SCLC cell lines and more than half of the cells examined
expressed TGF,B mRNA. About half of the examined cell
lines grew as monolayer cultures and half as floating aggre-
gates, but we could not detect any statistical difference
between the growth morphology and the expression of
TGFI-r or TGFP mRNAs (Chi-square test with Yates cor-
rection and Fisher's exact test, P <0.2). Coexpression of
TGF3-r and the ligand was found in six cell lines. These cell
lines therefore have the possibility of an autocrine growth
regulation. The question whether the SCLC cell lines produce
TGF, protein and if this is biologically active is currently
being investigated.
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